BIO-key International, Inc. (BKYI)

In Q3 2025, BIO-key reported a decrease in total revenues and a net loss, leading to a stock price decline. BIO-key partnered with IT2Trust, VaporVM, and SAVIS Group to expand its market reach. BIO-key and Visualforma were awarded a contract to secure digital identities for a large municipality in Portugal, causing the stock to soar, and BIO-key's EMEA subsidiary partnered with Citadel Global to expand its presence in India. The company launched its next-generation EcoID III USB fingerprint scanner and secured a significant new deployment for a Middle East defense sector organization. BIO-key raised $3.1 million in gross proceeds from a warrant exercise agreement and received an additional 180-day period from Nasdaq to meet the bid price rule. Chairman & CEO Michael DePasquale and Senior VP of Strategy & Compliance James Sullivan made several stock purchases. BIO-key presented at the DealFlow Discovery Investor Conference and is expected to release its next earnings report on March 26, 2026.

Explicit information regarding the seasonality of demand for BIO-key International, Inc.'s products and services is not readily available. The company's Q3 2025 revenue decrease was attributed to the absence of large orders from two long-time customers. BIO-key is actively working to expand its Annual Recurring Revenue (ARR), indicating a strategic move towards more predictable and recurring revenue streams. The company serves diverse sectors, which may have varying budget cycles and project timelines that could influence demand at different times of the year.

BIO-key International, Inc. specializes in fingerprint biometric identification and identity verification technologies, operating in the Industrials sector, specifically in Security & Protection Services, and as a computer software development firm. The company develops and markets identity and access management (IAM) solutions and biometric authentication technologies for commercial, government, and education sectors. Its major products and solutions include Identity and Access Management (IAM) Platforms like BIO-key PortalGuard and PortalGuard IDaaS solutions, Biometric Technologies like BIO-key VST and WEB-key products, Fingerprint Scanners and Readers, and other solutions like MobileAuth app, Single Sign-On, Self-Service Password Reset, and POS Terminal solutions.

BIO-key International, Inc. is headquartered in Holmdel, New Jersey, United States, and has a global presence. The company develops and markets its solutions in the United States and internationally, maintaining partnerships and market reach in various regions, including Europe, Asia, Scandinavia, the Middle East, Africa, India, Portugal, and Vietnam.

BIO-key International's brand reputation has been influenced by its ongoing efforts in product development, strategic partnerships, and financial performance. Securing new deployments for defense organizations and significant contracts have positively contributed to its reputation. However, the company has faced challenges, including stock volatility, a consensus "Sell" rating from analysts, a decrease in revenue in Q3 2025, and an extension from Nasdaq to meet its bid price rule.

BIO-key International, Inc. has 15 institutional owners and shareholders holding a total of 139,159 shares, including Vanguard Group Inc., Geode Capital Management, Llc., and Citadel Advisors Llc. Individual and insider ownership accounts for 3.71% of shares outstanding, while institutions hold 4.71%. Key individual owners include Michael W. DePasquale and Kelvin Wong.